Semaglutide Blood Tests Uk

Semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — is the most widely prescribed GLP-1 receptor agonist in the UK. Whether you are using it for type 2 diabetes management or weight loss, regular blood test monitoring is essential to track your progress, catch side effects early, and make sure your body is adapting safely to the medication.

This guide covers exactly which blood tests you need on semaglutide, when to take them, and what your results should look like at each stage of treatment.

Why Blood Tests Matter on Semaglutide

Semaglutide works by mimicking the hormone GLP-1. It slows gastric emptying, reduces appetite, improves insulin sensitivity, and triggers significant metabolic changes throughout your body. While these changes are overwhelmingly positive for most people, they need monitoring because:

• Rapid weight loss can deplete vitamins and minerals, particularly when food intake drops significantly.
• GI side effects (nausea, vomiting, diarrhoea) increase dehydration risk, which directly impacts kidney function.
• Liver enzyme changes can indicate either improvement (reduced fatty liver) or, in rare cases, drug-induced liver injury.
• Thyroid function may shift, especially if you are already on levothyroxine.
• Your prescriber needs objective data to decide on dose escalation, dose holds, or supplementation.

Blood tests turn guesswork into evidence. Without them, you are relying on how you feel — which is unreliable when your metabolism is changing this rapidly.

Semaglutide Dose Escalation: When to Test at Each Step

All semaglutide formulations follow a gradual dose escalation schedule to minimise side effects. Your blood testing schedule should align with these steps.

Injectable Semaglutide (Wegovy — Weight Management)

Injectable Semaglutide (Ozempic — Type 2 Diabetes)

Oral Semaglutide (Rybelsus)

Important: If you are unable to tolerate a dose increase and experience persistent vomiting or diarrhoea, test kidney function (creatinine, eGFR, urea) before your next scheduled panel. Dehydration from GI side effects is the primary cause of acute kidney injury reports associated with semaglutide.

The Six Blood Test Panels for Semaglutide Monitoring

Below is a detailed breakdown of each monitoring panel, why it matters when you are taking semaglutide, and what changes to expect.

1. Metabolic Panel: Blood Sugar Control

This is the headline panel for anyone taking semaglutide for type 2 diabetes, but it is equally relevant for weight management patients — particularly those with insulin resistance or prediabetes.

HbA1c is the gold-standard marker. NICE guidelines (NG28) recommend testing every three to six months until stable, then every six months. In clinical trials, semaglutide reduced HbA1c by 1.0–1.5% — a clinically significant improvement. If your HbA1c is not dropping after 3 months, it may indicate a need for dose adjustment or investigation into adherence or concurrent conditions.

2. Liver Function Panel: Safety Monitoring

The liver panel serves a dual purpose on semaglutide. First, it screens for rare drug-induced liver injury. Second — and more commonly — it tracks the improvement in liver health that most patients experience as fatty liver disease reverses with weight loss.

In the SUSTAIN and PIONEER trials, semaglutide treatment was associated with improvements in serum aminotransferase levels and reduced hepatic steatosis (fatty liver). According to the NCBI LiverTox database, serum enzyme elevations were no more common with semaglutide than with placebo.

However, if ALT or AST rise significantly above your baseline — particularly if accompanied by abdominal pain radiating to the back — this could indicate pancreatitis, a rare but serious side effect that requires immediate medical attention. Semaglutide carries a labelled warning for both pancreatitis and gallbladder disease.

Albumin deserves special attention. While it reflects liver function, it is also a marker of nutritional status. Declining albumin on semaglutide may indicate insufficient protein intake — a common issue when appetite is dramatically suppressed.

3. Kidney Function Panel: Dehydration Risk

Kidney monitoring is arguably the most important safety panel for semaglutide users. Post-marketing reports have documented cases of acute kidney injury, predominantly in patients experiencing severe GI side effects leading to dehydration.

The landmark FLOW trial, published in the New England Journal of Medicine, demonstrated that semaglutide reduced the risk of major kidney disease events by 24% and slowed eGFR decline by 1.16 ml/min/1.73m² per year compared to placebo. This is good news for long-term kidney health.

The risk, however, lies in the short term. Severe nausea, vomiting, or diarrhoea — common during dose escalation — can cause dehydration, which directly damages the kidneys. If your creatinine is rising or your eGFR is dropping, speak to your prescriber before continuing dose escalation.

4. Thyroid Function Panel: MTC Warning

Semaglutide carries a boxed warning (the most serious type of safety warning) regarding thyroid C-cell tumours. In animal studies, semaglutide caused dose-dependent increases in C-cell tumours in rodents. While human relevance has not been established — GLP-1 receptors are minimally expressed in human thyroid cells — the warning remains, and semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

In people with normal thyroid function, semaglutide does not significantly alter TSH or Free T4. However, if you are on levothyroxine for hypothyroidism, weight loss can reduce your medication requirements — TSH monitoring 6–8 weeks after starting semaglutide and again after significant weight loss is advisable to prevent overmedication.

Calcitonin (a marker of C-cell activity) rose above 10 pg/mL in approximately 0.3% of semaglutide users in clinical trials. While rare, it is worth discussing with your GP if you have any thyroid concerns. Note that routine calcitonin screening is not currently recommended by the MHRA or FDA for patients without risk factors.

Report any neck swelling, difficulty swallowing, shortness of breath, or persistent hoarseness to your doctor immediately — these could be symptoms of thyroid tumours.

5. Lipid Panel: Dramatic Improvements Expected

One of the most positive effects of semaglutide is its impact on cardiovascular risk markers. The lipid improvements go beyond what you would expect from weight loss alone — suggesting a direct metabolic benefit of GLP-1 receptor activation.

A 2025 meta-analysis of randomised controlled trials found that semaglutide significantly reduced total cholesterol, LDL, VLDL, and triglycerides, while modestly increasing HDL — even in non-diabetic adults with overweight or obesity. A 52-week study additionally showed redistribution of LDL and HDL subfractions toward a less atherogenic profile.

ApoB is particularly worth tracking as it reflects the actual number of atherogenic lipoprotein particles, providing a more accurate cardiovascular risk assessment than LDL alone.

If your lipids are not improving after 6 months, discuss statin therapy or other interventions with your prescriber.

6. Nutritional Panel: Deficiency Risk From Reduced Food Intake

This is the panel most commonly overlooked — and potentially the most important for your day-to-day wellbeing on semaglutide. When appetite drops dramatically and food intake is reduced by 30–40%, nutritional deficiencies are almost inevitable without conscious dietary planning or supplementation.

Vitamin B12 is the most well-documented deficiency. In one clinical study, mean B12 levels decreased significantly from 567 to 494 pg/mL over 12 months of treatment. Semaglutide slows gastric emptying and may interfere with intrinsic factor binding in the stomach, reducing B12 absorption independent of dietary intake.

Ferritin and iron levels should be watched carefully, especially in women of reproductive age. Reduced food intake combined with potential absorption changes can rapidly deplete iron stores, leading to fatigue that is easily mistaken for a normal side effect of the medication.

Vitamin D deficiency is already endemic in the UK (affecting an estimated 1 in 5 adults), and reduced dietary intake on semaglutide only compounds the problem.

CRP is worth including as a positive marker. Meta-analyses show semaglutide reduces high-sensitivity CRP by 38–55% compared to placebo — a significant anti-inflammatory benefit that goes beyond weight loss alone. In the STEP trials, CRP reductions reached 44–49% with the 2.4 mg dose. A rising CRP on semaglutide should prompt investigation rather than reassurance.

Recommended Monitoring Schedule

Semaglutide and Ozempic vs Wegovy vs Rybelsus: Does Monitoring Differ?

The active ingredient is the same across all three brands — semaglutide. The monitoring requirements are therefore identical, with one practical difference:

• Ozempic (0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg injection) — prescribed for type 2 diabetes. HbA1c monitoring is the primary outcome measure, tested every 3–6 months per NICE NG28. Kidney and liver function are standard components of annual diabetes reviews.
• Wegovy (0.25 mg to 2.4 mg injection) — prescribed for weight management. The longer dose escalation schedule (17 weeks to maintenance) means GI side effects and dehydration risk persist longer. Nutritional deficiency monitoring is arguably more important here due to greater caloric restriction.
• Rybelsus (3 mg, 7 mg, 14 mg oral tablets) — the oral formulation may have slightly different absorption characteristics but the same systemic effects. The same blood test panels apply.

For a detailed comparison of brand-specific monitoring considerations, see our Ozempic and Wegovy blood test monitoring guide.

What Happens If You Do Not Monitor?

Skipping blood tests on semaglutide is not dangerous for most people in the short term — but it creates blind spots that accumulate over time:

• Undetected B12 deficiency can cause irreversible nerve damage if left untreated for months.
• Subclinical kidney injury from dehydration may progress silently, particularly during dose escalation.
• Iron deficiency anaemia causes fatigue that patients attribute to the medication itself, leading to unnecessary discontinuation.
• Thyroid medication doses may become excessive after significant weight loss, causing palpitations, anxiety, and bone density loss.
• Without lipid data, you miss the opportunity to reduce or discontinue statins when semaglutide alone achieves target levels.

Regular blood testing empowers you and your prescriber to optimise treatment — not just tolerate it.

Frequently Asked Questions

What blood tests should I get before starting semaglutide?

A comprehensive baseline panel should include HbA1c, fasting glucose, liver function tests (ALT, AST, GGT, albumin), kidney function (creatinine, eGFR, urea), thyroid function (TSH, Free T4), a full lipid profile (cholesterol, triglycerides, non-HDL, ApoB), and nutritional markers (vitamin D, ferritin, iron, B12, CRP). The Core Health 45 blood test covers all of these in a single panel.

How often should I have blood tests while on semaglutide?

Test at baseline (before starting), 3 months, 6 months, and then annually. Additional kidney function tests are recommended if you experience significant gastrointestinal side effects such as persistent vomiting or diarrhoea during dose escalation. For diabetes patients, NICE recommends HbA1c testing every 3–6 months until stable.

Does semaglutide affect liver function tests?

In most patients, semaglutide improves liver function tests. Clinical trials show reductions in ALT and AST, particularly in those with elevated baseline values or non-alcoholic fatty liver disease. However, rare cases of drug-induced liver injury have been reported, so baseline and follow-up liver tests are recommended. A significant rise in liver enzymes accompanied by abdominal pain could indicate pancreatitis, which requires immediate medical attention.

Can semaglutide cause kidney problems?

Long-term, semaglutide appears to protect kidney function — the FLOW trial showed a 24% reduction in major kidney disease events. However, short-term kidney injury can occur secondary to dehydration from gastrointestinal side effects. This is why monitoring creatinine and eGFR during dose escalation is important, and adequate hydration should be maintained throughout treatment.

Does semaglutide cause vitamin deficiencies?

Yes — reduced food intake and altered nutrient absorption can lead to deficiencies in vitamin B12, iron, vitamin D, and other micronutrients. B12 deficiency is the most well-documented, with studies showing significant declines over 12 months of treatment. Blood testing at 3 and 6 months allows early detection and supplementation before symptoms develop.

Will semaglutide improve my cholesterol?

In most cases, yes. Clinical trials consistently show reductions in total cholesterol, LDL, triglycerides, and ApoB, with modest increases in HDL. These improvements occur in both diabetic and non-diabetic patients and appear to involve mechanisms beyond weight loss alone. Track your lipid panel at 3, 6, and 12 months to quantify the benefit.

Should I worry about thyroid cancer on semaglutide?

Semaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumours. However, human data has been largely reassuring — GLP-1 receptors are minimally expressed in human thyroid cells, and across multiple large studies, thyroid cancer incidence remained very low. The drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Discuss thyroid monitoring with your prescriber if you have any concerns.

Do I need to fast before a semaglutide monitoring blood test?

Yes — a 10–12 hour overnight fast is recommended for accurate fasting glucose, triglyceride, and lipid measurements. You can drink water freely. Take your semaglutide injection or Rybelsus tablet as normal on the day of your test (but after the blood draw if you take Rybelsus, as it must be taken on an empty stomach with a sip of water).